15 Feb1 The retractions came only weeks after BioMed Central.

Charlotte J http://www.montfordpharmacy.com . Haug, M.D., Ph.D.1 The retractions came only weeks after BioMed Central, an open-access publisher owned by Springer, retracted 43 articles for the same reason. How is it possible to fake peer review? Moon, who studies medicinal plant life, had set up a straightforward procedure. He gave journals tips for peer reviewers for his manuscripts, offering them with e-mail and titles addresses. But these addresses had been ones he created, so the requests to examine went directly to him or his co-workers.

Frohlich, M.D., and Paul F. Schellhammer, M.D. For the IMPACT Study Investigators: Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer Prostate cancer may be the most typical noncutaneous cancer among males in the United States and may be the second leading cause of death from malignancy in men.1 Localized prostate cancer may be cured with radiation or surgery treatment therapy, however the disease recurs in approximately 20 to 30 percent of individuals. Androgen-deprivation therapy, the most common treatment after recurrence, is effective, but the disease eventually progresses in most patients who receive such treatment.2 For guys with metastatic castration-resistant prostate cancers, the median survival in latest phase 3 studies has ranged from 12.2 to 21.7 months.3-9 A chemotherapeutic agent, docetaxel, is the only approved therapy that has been shown to prolong survival among men with this condition, conferring a median survival benefit of 2 to 3 three months, in comparison with mitoxantrone and prednisone.8-10 Combination therapy with mitoxantrone and also a glucocorticoid has been reported to provide palliation but no survival benefit, as compared with a glucocorticoid alone.11,12 Sipuleucel-T is an dynamic cellular immunotherapy, a kind of therapeutic tumor vaccine,13 consisting of autologous peripheral-blood mononuclear cells , including antigen-presenting cells , which have been activated ex vivo with a recombinant fusion proteins .